Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Vice President of Sales | January 01, 2019 | March 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date January 01, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2029-01-01 | Direct | 100,365 |
Reported balance
After 2019-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-01 · Grant · Acquired 100,365 · Balance 100,365 F1: On February 27, 2019, the Board of Directors of the Issuer determined that the fair market value of the Company's common stock as of January 1, 2019 was $2.20 per share. F2: 25% of the options were immediately exercisable, and the remaining options will vest in 36 equal monthly installments beginning on January 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 27, 2019, the Board of Directors of the Issuer determined that the fair market value of the Company's common stock as of January 1, 2019 was $2.20 per share.
F2: 25% of the options were immediately exercisable, and the remaining options will vest in 36 equal monthly installments beginning on January 1, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2019 Filed Mar 1, 2019 22:22 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 100,365 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001596771-19-000016 · primary_doc.xml · derivative · entry 1 Heuler Scott · CIK 0001763425 · Vice President of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,365 Underlying: Common Stock · 100,365 shares Expires 2029-01-01 F1 · derivative.exercise_price: On February 27, 2019, the Board of Directors of the Issuer determined that the fair market value of the Company's common stock as of January 1, 2019 was $2.20 per share. F2 · derivative.exercise_date: 25% of the options were immediately exercisable, and the remaining options will vest in 36 equal monthly installments beginning on January 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.